Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on July 7, 2022, regarding an event that occurred on July 6, 2022. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol AGLE.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the resignation of Sandesh Mahatme as a Class I director of the Board of Directors. His resignation is effective July 8, 2022. The company explicitly states that the resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the director departure. No unusual items were reported.
Investor Verification Checklist
- Verify the effective date of Sandesh Mahatme's resignation (July 8, 2022).
- Confirm the Board's statement that the resignation was not due to any disagreement.
- Check for subsequent filings regarding the appointment of a replacement director.
- Note that this filing does not contain financial results; refer to the latest 10-Q or 10-K for financial metrics.